The a2 Milk Company: How One Protein Claim Became a China Formula Bet

The a2 Milk Company is a brand built on a contested scientific idea that became one of the most profitable consumer businesses New Zealand has produced, almost entirely because of one product in one country. This article explains where the A1/A2 proposition came from, how the company makes money without owning cows, how the daigou channel created and then nearly broke it, why it has moved into manufacturing, what the 2025-2026 numbers show and what could go wrong in a Chinese market where births are falling. It is part of the New Zealand Company Stories hub.

How did the a2 Milk Company start?

The company was founded in New Zealand in 2000 as A2 Corporation by scientist Corran McLachlan and entrepreneur Howard Paterson. It began as an intellectual-property business built on a genetic test that identifies cows producing only A2 beta-casein.

McLachlan’s hypothesis was that the A1 variant of beta-casein, common in European dairy breeds, releases a peptide during digestion that some people tolerate poorly, while the older A2 variant does not. The company patented methods for testing herds and intended to license them to dairy processors. Both founders died in 2003, and the early years were marked by regulatory rebukes over health claims and by a mainstream dairy industry that treated the idea as a threat.

The turn came in Australia, where the company took direct control of a fresh-milk brand and built it into a premium supermarket product with a share of around a tenth of the category by value. Infant formula followed in 2013 under the a2 Platinum label, manufactured under contract by Synlait in Canterbury. The business was renamed The a2 Milk Company in 2014 and added an ASX listing in 2015, just as Chinese demand for foreign formula was accelerating.

What is the A1 versus A2 claim, and does the science hold?

The claim is that milk containing only A2 beta-casein is easier for some people to digest than ordinary milk, which contains a mixture of A1 and A2. Evidence supports modest digestive-comfort effects in some studies; broader disease claims have not been established.

Regulators have been cautious. A European Food Safety Authority review in 2009 found no demonstrated cause-and-effect relationship between the peptide derived from A1 beta-casein and non-communicable diseases. Later trials, several of them funded by the company, reported less digestive discomfort among people who believe they are intolerant to milk. The company’s marketing today confines itself to that territory and to the simple statement that its products are naturally free of A1 protein.

Commercially, the scientific debate matters less than it once did. The original patents have largely expired, and competitors including Nestlé and several Chinese formula makers now sell A2-protein products. What a2 retains is the brand: it owns the idea in consumers’ minds, in the way a first mover in any category often does. The lesson is that a differentiated claim buys time to build a brand, not a permanent moat.

How does a2 Milk make money?

The a2 Milk Company earns a premium price on branded dairy products, historically without owning farms or large factories. Infant formula for Chinese consumers provides most of the profit; liquid milk in Australia and the United States provides volume and brand presence.

Infant formula reaches Chinese parents by two legally distinct routes. China-label product carries Chinese packaging, is registered with the State Administration for Market Regulation (SAMR) and is sold through mother-and-baby stores and domestic e-commerce. English-label product is the same brand in Australian and New Zealand packaging, sold through cross-border e-commerce platforms and by resellers. English-label needs no Chinese recipe registration but depends on cross-border trade rules staying liberal.

The model is unusually capital-light and cash-generative. Farmers are paid a premium to supply segregated milk from tested herds; contract manufacturers turn it into powder; a2 spends heavily on marketing and keeps the margin. EBITDA was NZ$274.3 million in FY25 on revenue of about NZ$1.9 billion, and the company held enough cash to declare its first ordinary dividend that year. The contrast with a commodity processor’s economics is clear from the Fonterra story.

How did the daigou channel make and then break the company?

Daigou, informal traders who buy goods abroad and resell them to consumers in China, built a2 Platinum’s reputation at almost no marketing cost. When Covid-19 closed borders in 2020, the channel collapsed, inventory piled up and a2’s earnings fell by more than half.

After the 2008 melamine scandal, Chinese parents distrusted domestic formula and paid large premiums for foreign tins bought in foreign shops. Students, tourists and professional shoppers cleared Australian supermarket shelves and shipped the product home. For a2 this was a gift: recommendation by trusted individuals did the work of advertising. Revenue reached NZ$1.73 billion in FY20, with an EBITDA margin above 30%, and the share price peaked at more than NZ$20.

The weakness was visibility. The company did not know precisely who was buying, how much stock sat in the channel or what price it was selling for. When international travel stopped, daigou volumes evaporated; product was discounted, older stock had to be written down and guidance was cut four times in the 2021 financial year. Revenue fell to about NZ$1.2 billion and the shares lost roughly three-quarters of their value.

David Bortolussi, who became chief executive in February 2021, rebuilt the business around channels the company could see and control: China-label distribution through its state-owned partner, direct relationships with cross-border platforms and far more marketing inside China.

Who owns a2 Milk and how is it governed?

The a2 Milk Company is a widely held public company listed on both the NZX and the ASX, with no controlling shareholder. Its register is dominated by Australasian and global institutional investors, and most of its senior management is based in Australia.

That makes it the odd one out in New Zealand dairy, an industry otherwise organised around farmer co-operatives and foreign-controlled processors. The company’s most important relationships are contractual: with China Animal Husbandry Group, the state-owned enterprise that has long acted as its exclusive import agent for China-label product, and with Synlait, in which a2 holds about 19.8%. Dual listing gives it access to a deeper pool of capital than the local exchange offers, a pattern examined in the piece on the NZX and its shrinking market.

Capital management has become a governance issue in its own right. For years the company sat on a cash pile approaching NZ$1 billion, to the irritation of shareholders. The response has been an ordinary dividend from FY25, a final FY26 dividend of 9.5 cents per share, and a NZ$300 million special dividend tied to the reshaping of its supply chain.

Why did a2 Milk decide to own a factory?

Chinese rules attach each infant-formula registration to a specific manufacturing site, so a brand that does not own a registered plant does not fully control its own product. In 2025 a2 bought a plant at Pōkeno with two China-label registrations for about NZ$282 million.

For a decade a2’s China-label formula was made at Synlait’s Dunsandel plant under an exclusive arrangement. As Synlait’s finances deteriorated, the dependence became a strategic risk, and the two companies fought over exclusivity terms before settling in 2024 as part of the rescue described in the Synlait and Bright Dairy story. A first attempt at vertical integration, a 75% stake in Mataura Valley Milk in Southland bought in 2021, gave a2 a dryer but no formula registrations.

The 2025 transactions corrected course. The company acquired the former Yashili New Zealand plant at Pōkeno, south of Auckland, and committed to invest more than NZ$100 million in its capacity and capability. It sold Mataura Valley Milk to Open Country Dairy for roughly NZ$100 million, accepting a loss on divestment of about NZ$130 million, while keeping a supply agreement for A1-free ingredients. SAMR has since approved the transition of two China-label registrations, opening the way for a2 to manufacture its own registered product alongside what Synlait makes.

What do the 2025-2026 numbers show?

FY26 revenue was NZ$1,974.9 million, up 12.4%, but net profit after tax from continuing operations fell 5.8% to NZ$207.4 million. EBITDA of about NZ$284 million was slightly lower than the prior year on a comparable basis.

Growth came from English-label infant formula, other nutritional products and liquid milk. China-label formula, the core of the business, went backwards: sales fell by about 14% after a fourth-quarter disruption in which freight constraints, production backlogs at Synlait and new customs requirements left shelves short. Some customers switched to rival brands. Management said stock levels had since been restored.

The other drag was Pōkeno, which ran at an operating loss in its first year under a2 ownership while volumes ramped up. Guidance for FY27 is mid-single-digit revenue growth weighted to the second half, an EBITDA margin of approximately 15%, and Pōkeno approaching break-even. Analysts trimmed earnings forecasts after the result while generally leaving the long-term China thesis intact.

The balance sheet remains a strength. Cash conversion was better than guided, and the NZ$300 million special dividend returns surplus capital while leaving ample funding for the plant investment.

Who are a2 Milk’s competitors?

In China, a2 competes with domestic leaders such as Feihe, Yili and Junlebao and with multinationals including Danone, Nestlé and FrieslandCampina. It ranks among the top handful of brands in China-label formula and is stronger still in cross-border English-label sales.

The domestic brands have gained ground since the daigou era. They have rebuilt consumer trust, dominate distribution in lower-tier cities and benefit from an official preference for local production. Many now market their own A2-protein lines, which narrows the gap between a2 and the field on product claim even as its brand recognition stays high.

The multinationals compete at the premium end with large research budgets and with specialised formulas. In the other markets, competition is more conventional: private-label and branded fresh milk in Australia, and a crowded premium dairy aisle in the United States, where a2 has grown quickly but has yet to demonstrate sustained profitability. Among New Zealand peers, the nearest comparison is not another dairy company but export brands that trade on provenance, such as those described in the article on Allbirds and Icebreaker.

What are the main risks facing a2 Milk?

The chief risks are China’s falling birth rate, regulatory change, supply-chain concentration and execution at Pōkeno. The company is exposed to one product category in one country to a degree unusual for a business of its size.

Supply risk was demonstrated in the final quarter of FY26. Until Pōkeno is producing registered China-label product at scale, a2 depends on a single third-party site at Dunsandel, owned by a company that has itself only recently been stabilised. Owning a factory cures one problem and introduces another: fixed costs. A business that used to flex its cost base with demand must now fill a plant.

Trade politics sit in the background. New Zealand’s access to China rests on the arrangements described in the article on the New Zealand-China free-trade agreement; a deterioration in that relationship would be felt by every exporter of consumer goods.

What can founders and CFOs learn from a2 Milk?

The a2 story teaches that a channel a company cannot see is a channel it does not control, and that asset-light models carry hidden dependence on whoever holds the scarce permission. It also shows the value of a simple claim, held consistently.

• Know where the inventory is. Daigou sales looked like effortless growth until borders closed. Sell-in is not sell-through; invest in channel data before it is needed.
• Build the brand before the patent expires. The A2 testing patents lapsed, but two decades of single-minded positioning left a brand that competitors with the same protein cannot easily displace.
• Diversify suppliers when it is cheap. Dependence on one manufacturer was tolerable while that manufacturer was healthy. Fixing it later cost hundreds of millions of dollars.
• Take the write-off. Selling Mataura Valley Milk at a loss of about NZ$130 million was painful but freed capital for the asset that actually carried registrations.
• Return idle cash. A large cash balance with no stated purpose invites pressure; a dividend policy and a special payout turned a criticism into a strength.

More operating lessons from founders who built global businesses from small home markets are collected in the Founders Hub.

What happens next for a2 Milk?

The next two years are about making Pōkeno work and winning back the China-label share lost in mid-2026. Management expects infant-formula sales to be broadly flat in FY27 while the plant moves towards break-even.

The medium-term plan rests on three moves. First, shift a growing portion of China-label production to the company’s own registered site, which should lift margins once the plant is full. Second, broaden the range beyond infant formula into fortified milk powders for children and older adults, categories less exposed to the birth rate. Third, keep expanding in the United States and in newer Asian markets so that China is a smaller share of the whole.

The open questions concern relationships. Synlait remains both a supplier and an investment, and the terms on which volume migrates from Dunsandel to Pōkeno will shape both companies. China Animal Husbandry Group remains the gatekeeper for distribution. If the company executes, it emerges as an integrated nutrition business with its own regulatory licences; if demand disappoints, it will own a half-empty factory in a shrinking category.

Frequently Asked Questions